Cerylid regroups, lays off staff
Thursday, 04 September, 2003
Unlisted Melbourne company Cerylid Biosciences has reorganised, necessitating the layoff of a portion of its staff.
But management at the natural products drug discovery company was quick to reassure Australian Biotechnology News that the strategy is not a sign of trouble for the company, but rather a step taken to realign the needs of the business.
"The reorganisation is due to a realignment of projects, and the company's needs going forward," said Cerylid CEO Dr Jackie Fairley.
"Like many in the sector, we're keeping an eye on cash burn, but we're in a strong cash position, with two years of cash available."
Osteoarthritis study uncovers new genetic links, drug targets
The genome-wide association study (GWAS) uncovered over 900 genetic associations, more than 500...
How brain cells are affected by Tourette syndrome
US researchers have conducted a cell-by-cell analysis of brain tissue from individuals with...
Preventing neural graft rejection in Parkinson's patients
Researchers have engineered a way to fool the immune system into accepting neural grafts as part...
